Holen Sie sich die Stockscreener-App
7.47
3.11%
-0.24
Schlusskurs vom Vortag:
$7.71
Offen:
$7.79
24-Stunden-Volumen:
1.28M
Relative Volume:
0.73
Marktkapitalisierung:
$1.04B
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.9056
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+3.89%
1M Leistung:
+18.38%
6M Leistung:
+63.46%
1J Leistung:
-22.03%
1-Tages-Spanne:
$7.375
$7.89
1-Wochen-Bereich:
$7.01
$7.89
52-Wochen-Spanne:
$4.155
$10.01
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
7.47 | 1.07B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Can Vir Biotechnology Inc. stock hit analyst price targetsJuly 2025 Rallies & Low Risk Growth Stock Ideas - mfd.ru
How cyclical is Vir Biotechnology Inc.’s revenue stream2025 Market Sentiment & Technical Pattern Based Signals - mfd.ru
Vir Biotechnology, Inc. (VIR) Stock Analysis: A 111.85% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Is Vir Biotechnology Inc. subject to activist investor interestJuly 2025 Earnings & Weekly High Potential Stock Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - PharmiWeb.com
Vir Biotechnology to unveil Q4 and full year 2025 earnings results - Traders Union
Press Release: Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - 富途牛牛
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating for VIR with $14 Price Target | VI - GuruFocus
VIR News Today | Why did Vir Biotechnology stock go down today? $VIR - MarketBeat
Vir Biotechnology: The Low-Down On The Readouts Ahead - Seeking Alpha
Vir Biotechnology price target lowered to $24 from $31 at Barclays - TipRanks
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Sato sells $169k in stock By Investing.com - Investing.com Canada
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown - MSN
Vir Biotechnology, Inc. (VIR) Stock Analysis: A Biotech with a Promising 131% Upside Potential - DirectorsTalk Interviews
Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial - Yahoo Finance
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trading Recap: What makes Stran Company Inc Equity Warrant stock attractive today2025 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Update: Can Vir Biotechnology Inc outperform under higher oil pricesJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9%Should You Buy? - MarketBeat
Aug Macro: Can BankUnited Inc outperform under higher oil prices2025 Risk Factors & Daily Market Momentum Tracking - baoquankhu1.vn
Aug Final Week: Is Vir Biotechnology Inc a strong growth stock2025 Investor Takeaways & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (NASDAQ:VIR) Top 10 Nasdaq Stocks Spotlight on Research - Kalkine Media
Vir Biotechnology (VIR) Advances in Hepatitis Delta Treatment - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Trading 7.3% HigherWhat's Next? - MarketBeat
Vir Biotechnology shows positive results in hepatitis delta trial - Traders Union
Vir Biotechnology (VIR) Reports Positive Trial Results in Hepati - GuruFocus
Vir Biotechnology reports promising results for hepatitis delta therapy By Investing.com - Investing.com Nigeria
Vir Biotechnology reports promising results for hepatitis delta therapy - Investing.com
Vir Biotechnology reports positive Phase 2 hepatitis delta data, outlines 2026 clinical milestones - MSN
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - BioSpace
Vir Biotechnology advances hepatitis delta program and cash runway - TipRanks
Vir Biotechnology provides updates on chronic hepatitis Delta and oncology programs and upcoming 2026 clinical milestones - marketscreener.com
Vir Biotechnology reports positive hepatitis delta trial data - StreetInsider
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones - TradingView — Track All Markets
How Vir Biotechnology Inc. stock performs after earnings2025 Biggest Moves & Verified Momentum Stock Watchlist - ulpravda.ru
Is Vir Biotechnology Inc. stock a safe haven assetWeekly Profit Analysis & Weekly Stock Breakout Alerts - Улправда
Will Vir Biotechnology Inc. stock keep outperforming rivalsJuly 2025 Big Picture & Low Risk Investment Opportunities - Улправда
Profit Recap: Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Summary Report & Free High Accuracy Swing Entry Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - Bộ Nội Vụ
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vir Biotechnology Inc-Aktie (VIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Feb 02 '26 |
Sale |
7.71 |
22,000 |
169,671 |
1,144,391 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):